聚乙二醇化赛妥珠单抗，一种用于对抗眼部炎症的新型抗TNF-α药物。
Certolizumab Pegol, a New Anti-TNF-α in the Armamentarium against Ocular Inflammation.
作者信息
Llorenç Victor, Mesquida Marina, Sainz de la Maza Maite, Blanco Ricardo, Calvo Vanesa, Maíz Olga, Blanco Ana, de Dios-Jiménez de Aberásturi Juan Ramón, Adán Alfredo
机构信息
a Clínic Institute of Ophthalmology (ICOF), Hospital Clínic of Barcelona , Barcelona , Spain .
b Department of Rheumatology , Marqués de Valdecilla Hospital , Santander , Spain .
出版信息
Ocul Immunol Inflamm. 2016;24(2):167-72. doi: 10.3109/09273948.2014.967779. Epub 2014 Oct 17.
PURPOSE
To study the efficacy and tolerance of certolizumab pegol (CZP) in active uveitis.
METHODS
Retrospective case series at 4 referral centers. Patients treated with CZP for active uveitis during at least 6 months were eligible. Inflammation by SUN scores, visual acuity (VA) (logMAR), and central macular thickness (CMT) were compared from baseline until final follow-up. Quiescence was defined as 0+ to 0.5+ in anterior chamber and vitreous haze scores and no CMT increase.
RESULTS
Four males and 3 females (14 eyes) were included, mean age 42.4 ± 8.8 years. All were long-lasting chronic-relapsing uveitis with prior failure to other anti-TNF-α. After a mean follow-up of 10.4 ± 4.8 months, 5/7 patients (71.4%) achieved quiescence with CZP. VA improved significantly from +0.52 ± 0.68 to +0.45 ± 0.68 (p = 0.032) at 1 month and to +0.44 ± 0.64 (p = 0.035) at 6 months. No adverse events were found.
CONCLUSION
CZP can be an effective alternative in refractory uveitis.
目的
研究聚乙二醇化赛妥珠单抗（CZP）治疗活动性葡萄膜炎的疗效和耐受性。
方法
4个转诊中心的回顾性病例系列研究。纳入至少接受6个月CZP治疗活动性葡萄膜炎的患者。比较从基线到最终随访时的SUN评分炎症、视力（VA）（logMAR）和中心黄斑厚度（CMT）。静止状态定义为前房和玻璃体混浊评分为0+至0.5+且CMT无增加。
结果
纳入4例男性和3例女性（14只眼），平均年龄42.4±8.8岁。所有患者均为长期慢性复发性葡萄膜炎，之前使用其他抗TNF-α治疗失败。平均随访10.4±4.8个月后，5/7例患者（71.4%）使用CZP达到静止状态。VA在1个月时从+0.52±0.68显著改善至+0.45±0.68（p = 0.032），在6个月时改善至+0.44±0.64（p = 0.035）。未发现不良事件。
结论
CZP可作为难治性葡萄膜炎的一种有效替代治疗方法。
Zotero 插件